Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.66 |
| ▸ | KMO | O15229 | 3/20 | 0.56 |
| ▸ | CNR1 | P21554 | 7/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30680327 | 1.00 | CNR2 (0.66) | CNR2KMOCNR1MAP4K4PTGER1 | |
| SCHEMBL30680252 | 0.88 | KMO (0.59) | CNR2KMOCNR1MAP4K4 | |
| SCHEMBL20594053 | 0.88 | KMO (0.59) | CNR2KMOCNR1MAP4K4 | |
| SCHEMBL20594095 | 0.86 | KMO (0.51) | CNR2KMOCNR1PTGER1 | |
| SCHEMBL30680237 | 0.86 | KMO (0.51) | CNR2KMOCNR1PTGER1 | |
| SCHEMBL411891 | 0.82 | MAP4K4 (0.49) | CNR2KMOMAP4K4 | |
| SCHEMBL20594044 | 0.82 | CNR2 (0.67) | CNR2CNR1 | |
| SCHEMBL26095416 | 0.81 | CNR2 (0.61) | CNR2CNR1 | |
| SCHEMBL411937 | 0.81 | CNR1 (0.52) | CNR2KMOCNR1MAP4K4 | |
| SCHEMBL411448 | 0.81 | CNR2 (0.55) | CNR2KMOCNR1PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110753690-B | Pyridine derivatives | 豪夫迈·罗氏有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-3642200-B1 | PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-03 | — | — | EP | disclosed |
| US-20220064178-A1 | PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-03-03 | — | — | US | disclosed |
| US-11117903-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200239490-A1 | PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3642200-A1 | PYRIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2020-04-29 | — | — | EP | disclosed |
| CN-110753690-A | Pyridine derivatives | 豪夫迈·罗氏有限公司 | 2020-02-04 | — | — | CN | disclosed |
| WO-2018234284-A1 | PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-27 | — | — | WO | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729105-B2 | Heteroarylmethyl amides | HOFFMANN LA-ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2613785-A1 | HETEROARYLMETHYL AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| CN-103118680-A | Heteroarylmethyl amides | HOFFMANN LA ROCHE | 2013-05-22 | — | — | CN | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064178-A1 | PYRIDINE DERIVATIVES | NDUFS6, NDUFS3, CYP11B2 | CNR2 69/4885KMO 1836/4885CNR1 26/4885 |
| US-20200239490-A1 | PYRIDINE DERIVATIVES | NDUFS6, NDUFS3, CYP11B2 | CNR2 69/4885KMO 1836/4885CNR1 26/4885 |
| US-11117903-B2 | Pyridine derivatives | NDUFS6, NDUFS3, CYP11B2 | CNR2 69/4885KMO 1836/4885CNR1 26/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | CNR2 435/4885KMO 2423/4885CNR1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.